Springworks Therapeutics, Inc.

Todd Shearer

Uchenna H Iloeje

Abraham J Langseth

Kristin Patterson

Rex Williams

Shinta Cheng

Allison Lim

The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.

Mirdametinib treatment

The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUCless than 400 ng·h/mL, (ii) a Cno more than 40 ng/mL, or (iii) both.

The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.

Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib

Non-linear dosing of mirdametinib

The present disclosure relates to improved methods of treatment with nirogacestat.

Growing community of inventors

Stamford, CT, United States of America

Todd Shearer